Panacea Acquisition today filed a third amended S-4 covering its proposed merger with Nuvation Bio. The filing adds an indemnification agreement with Panacea’s board and officers, the full agreement and merger plan, and opinion of counsel.
In addition to the approximately $144 million held in Panacea’s trust (assuming no redemptions), transaction terms also include concurrent equity financings totaling slightly more than $500 million at $10 per share.
Nuvation Bio is focused on developing cancer treatments. Read more.
